<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Anxiolytics and Hypnotics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int404-anxiolytics-and-hypnotics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int404-anxiolytics-and-hypnotics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int404-anxiolytics-and-hypnotics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int403-zidovudine.htm" title="Previous: Zidovudine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1114-melatonin.htm" title="Next: Melatonin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Anxiolytics and Hypnotics</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Anxiolytics and Hypnotics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span>enhanced hypotensive and sedative effects when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>alpha-blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>general anaesthetics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int252-antidepressants-tricyclic-related.htm">Antidepressants, Tricyclic (related)</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>tricyclic-related antidepressants</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int303-antihistamines.htm">Antihistamines</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>antihistamines</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</p></div></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>antipsychotics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>baclofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int607-lofexidine.htm">Lofexidine</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>lofexidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>methyldopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>opioid analgesics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>anxiolytics and hypnotics</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span>increased sedative effect when </span> <span>anxiolytics and hypnotics</span> <span>given with</span> <span>tizanidine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Melatonin</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>melatonin</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>melatonin</span> <span>increased by</span> <span>fluvoxamine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>plasma concentration of </span> <span>melatonin</span> <span>increased by</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr></tbody></table><p><strong>Benzodiazepines</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>benzodiazepines</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>serious adverse events reported with concomitant use of </span> <span>benzodiazepines</span> <span>and</span> <span>clozapine</span> <span>(causality not established)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span>metabolism of </span> <span>benzodiazepines</span> <span>inhibited by</span> <span>disulfiram</span> <span>(increased sedative effects)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>plasma concentration of some </span> <span>benzodiazepines</span> <span>increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span></span> <span>benzodiazepines</span> <span>possibly antagonise effects of</span> <span>levodopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>sedative effects possibly increased when </span> <span>benzodiazepines</span> <span>given with</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td class="cAI"><p><span>increased risk of hypotension, bradycardia and respiratory depression when parenteral</span> <span>benzodiazepines</span> <span>given with intramuscular</span> <span>olanzapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>benzodiazepines</span> <span>possibly increase or decrease plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>benzodiazepines</span> <span>possibly accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td class="cAI"><p><span></span> <span>benzodiazepines</span> <span>enhance effects of</span> <span>sodium oxybate</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span>effects of </span> <span>benzodiazepines</span> <span>possibly reduced by</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Alprazolam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>alprazolam</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>plasma concentration of </span> <span>alprazolam</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>alprazolam</span> <span>possibly increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>increased risk of prolonged sedation when </span> <span>alprazolam</span> <span>given with</span> <span>indinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma concentration of </span> <span>alprazolam</span> <span>increased by</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span> <span>alprazolam</span> <span>increased by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>alprazolam</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr></tbody></table><p><strong>Chlordiazepoxide</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> but has no specific interaction information.</p><p><strong>Clobazam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1144-stiripentol.htm">Stiripentol</a></td><td><p><span>plasma concentration of </span> <span>clobazam</span> <span>increased by</span> <span>stiripentol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>clobazam</span> <span>possibly increases plasma concentration of</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Clonazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>clonazepam</span> <span>often reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of neurotoxicity when </span> <span>clonazepam</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>clonazepam</span> <span>often reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>clonazepam</span> <span>often reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>increased risk of side-effects when </span> <span>clonazepam</span> <span>given with</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Diazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td><p><span>metabolism of </span> <span>diazepam</span> <span>possibly inhibited by</span> <span>esomeprazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>diazepam</span> <span>increased by</span> <span>fluconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td><p><span>metabolism of </span> <span>diazepam</span> <span>inhibited by</span> <span>isoniazid</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>plasma concentration of </span> <span>diazepam</span> <span>possibly increased by</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>metabolism of </span> <span>diazepam</span> <span>possibly inhibited by</span> <span>omeprazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>diazepam</span> <span>increases or decreases plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td><p><span>plasma concentration of </span> <span>diazepam</span> <span>possibly increased by</span> <span>progestogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>diazepam</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>diazepam</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>diazepam</span> <span>possibly increased by</span> <span>valproate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>diazepam</span> <span>increased by</span> <span>voriconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr></tbody></table><p><strong>Flurazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>flurazepam</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr></tbody></table><p><strong>Loprazolam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> but has no specific interaction information.</p><p><strong>Lorazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span> <span>lorazepam</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>lorazepam</span> <span>possibly increased by</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Lormetazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> but has no specific interaction information.</p><p><strong>Midazolam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>aprepitant</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>atazanavir</span> <span>—avoid concomitant use of oral<span>midazolam</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>plasma concentration of oral</span> <span>midazolam</span> <span>increased by</span> <span>boceprevir</span> <span>—manufacturer of <span>boceprevir</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>midazolam</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>midazolam</span> <span>inhibited by</span> <span>clarithromycin</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1072-deferasirox.htm">Deferasirox</a></td><td><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly reduced by</span> <span>deferasirox</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>metabolism of </span> <span>midazolam</span> <span>inhibited by</span> <span>diltiazem</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>increased risk of prolonged sedation when </span> <span>midazolam</span> <span>given with</span> <span>efavirenz</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>midazolam</span> <span>inhibited by</span> <span>erythromycin</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td><p><span>metabolism of </span> <span>midazolam</span> <span>possibly inhibited by</span> <span>fentanyl</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>fluconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of oral</span> <span>midazolam</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>indinavir</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>itraconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>ketoconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span></span> <span>midazolam</span> <span>increases absorption of</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>nelfinavir</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>nilotinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>posaconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>saquinavir</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of oral</span> <span>midazolam</span> <span>possibly reduced by</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>possibly increased by</span> <span>telaprevir</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>midazolam</span> <span>inhibited by</span> <span>telithromycin</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>metabolism of </span> <span>midazolam</span> <span>inhibited by</span> <span>verapamil</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>midazolam</span> <span>increased by</span> <span>voriconazole</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr></tbody></table><p><strong>Nitrazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span> <span>nitrazepam</span> <span>possibly reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Oxazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> but has no specific interaction information.</p><p><strong>Temazepam</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span>increased risk of </span> <span>temazepam</span> <span>toxicity when given with</span> <span>disulfiram</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Buspirone</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>plasma concentration of </span> <span>buspirone</span> <span>increased by</span> <span>diltiazem</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span> <span>buspirone</span> <span>increased by</span> <span>erythromycin</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>buspirone</span> <span>increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>buspirone</span> <span>increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma concentration of </span> <span>buspirone</span> <span>increased by</span> <span>itraconazole</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>manufacturer of </span> <span>buspirone</span> <span>advises avoid concomitant use with</span> <span>MAOIs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int1224-methylthioninium.htm">Methylthioninium</a></td><td class="cAI"><p><span>possible risk of CNS toxicity when </span> <span>buspirone</span> <span>given with</span> <span>methylthioninium</span> <span>—avoid concomitant use (if avoidance not possible, use lowest possible dose of <span>methylthioninium</span> and observe patient for up to 4 hours after administration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>buspirone</span> <span>possibly accelerated by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>buspirone</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int260-tranylcypromine.htm">Tranylcypromine</a></td><td><p><span>avoidance of </span> <span>buspirone</span> <span>for 10 days after stopping</span> <span>tranylcypromine</span> <span>advised by manufacturer of <span>tranylcypromine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>plasma concentration of </span> <span>buspirone</span> <span>increased by</span> <span>verapamil</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>Chloral</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>chloral</span> <span>may transiently enhance anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int542-furosemide.htm">Furosemide</a></td><td><p><span>administration of </span> <span>chloral</span> <span>with parenteral</span> <span>furosemide</span> <span>may displace thyroid hormone from binding sites</span>  </p></td><td></td></tr></tbody></table><p><strong>Clomethiazole</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>clomethiazole</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Meprobamate</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> but has no specific interaction information.</p><p><strong>Zaleplon</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>zaleplon</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>zaleplon</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Zolpidem</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>zolpidem</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration and reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>zolpidem</span> <span>possibly increased by</span> <span>ritonavir</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td><p><span>sedative effects possibly increased when </span> <span>zolpidem</span> <span>given with</span> <span>sertraline</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Zopiclone</strong> belongs to <strong>Anxiolytics and Hypnotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>metabolism of </span> <span>zopiclone</span> <span>inhibited by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span> <span>zopiclone</span> <span>significantly reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1114-melatonin.htm" title="Melatonin">Melatonin</a></li><li id="_bnf_int405-benzodiazepines"><a href="bnf_int405-benzodiazepines.htm" title="Benzodiazepines">Benzodiazepines</a></li><li><a href="bnf_int427-buspirone.htm" title="Buspirone">Buspirone</a></li><li><a href="bnf_int422-chloral.htm" title="Chloral">Chloral</a></li><li><a href="bnf_int423-clomethiazole.htm" title="Clomethiazole">Clomethiazole</a></li><li><a href="bnf_int428-meprobamate.htm" title="Meprobamate">Meprobamate</a></li><li><a href="bnf_int904-zaleplon.htm" title="Zaleplon">Zaleplon</a></li><li><a href="bnf_int425-zolpidem.htm" title="Zolpidem">Zolpidem</a></li><li><a href="bnf_int426-zopiclone.htm" title="Zopiclone">Zopiclone</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int403-zidovudine.htm">Previous: Zidovudine</a> | <a class="top" href="bnf_int404-anxiolytics-and-hypnotics.htm#">Top</a> | <a accesskey="]" href="bnf_int1114-melatonin.htm">Next: Melatonin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>